PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA (English)
- New search for: Omelyanovskiy, V.
- New search for: Avxentyeva, M.
- New search for: Sura, M.
- New search for: Savilova, A.G.
- New search for: Khachatryan, G.R.
- New search for: Omelyanovskiy, V.
- New search for: Avxentyeva, M.
- New search for: Sura, M.
- New search for: Savilova, A.G.
- New search for: Khachatryan, G.R.
In:
Value in health
;
21
, 3
;
S62-S63
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIA
-
Contributors:Omelyanovskiy, V. ( author ) / Avxentyeva, M. ( author ) / Sura, M. ( author ) / Savilova, A.G. ( author ) / Khachatryan, G.R. ( author )
-
Published in:Value in health ; 21, 3 ; S62-S63
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2018-01-01
-
Size:S62-S63
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610.28
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610.28 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 21, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
Editorial Board| 2018
-
PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE: REALITIES, CHALLENGES AND PERSPECTIVESBaseilhac, E. / Dorizon, D. / Heng, C. et al. | 2018
-
PCV157 - ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND ATRIAL FIBRILLATION SYMPTOM BURDEN: RESULTS OF A STUDY ON ATRIAL FIBRILLATION PATIENTS IN GERMANY, SWEDEN AND SWITZERLANDWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENSRu, H. / Zhou, J. et al. | 2018
-
PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS' EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESISKarácsony, I. / Balogh, B. / Szabó, L. / Oláh, A. / Ipolyi, D. / Brantmüller, É. / Boncz, I. / Pakai, A. et al. | 2018
-
PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKINGChew, V.C. / Sogokon, P. / McNamara, L. / Morrison, S. et al. | 2018
-
PHP356 - COMPARATIVE ANALYSIS BETWEEN OLD AND NEW ITALIAN INNOVATION RATING SYSTEMPrada, M. / Sansone, C. / Mariano, E.E. / Mantovani, M. et al. | 2018
-
PIH4 - HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH EXTREMELY PRETERM BIRTH IN THE NETHERLANDSHouben, E. / Siffel, C. / Overbeek, J.A. / Sarda, S.P. et al. | 2018
-
PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGALMirco, A. / Paulino, E. / Farinha, M.H. / Gil, A. / Shepherd, J. / Badia, X. et al. | 2018
-
PHP194 - THE EMA CLINICAL DATA WEBSITE: A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONSLehmann, S. / Allard, R. / Boehler, Y. et al. | 2018
-
PHP195 - DO COMPANIES' MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY'S COMPLEX PAYER MARKETPLACE?Bailey, S. / Hewitt, C. / Craddy, P. / Foxon, G. et al. | 2018
-
PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONSvan de Rijt, J. / Severens, J.L. / van Baal, P. / Knies, S. et al. | 2018
-
PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE: AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIESLi, L. / Liu, B. et al. | 2018
-
PHP137 - CHANGES IN THE NUMBER OF NURSING WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Gratz, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL: A REVIEW OF 18 YEARS OF PROGRESSSaggia, M.G. et al. | 2018
-
PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Boncz, I. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Endrei, D. et al. | 2018
-
PHP129 - CHALLENGES AND OPPORTUNITIES IN THE BIOLOGICALS-BIOSIMILARS MARKET: SUSTAINABILITY AND MARKET DIFFERENTIATIONGarcía-Goñi, M. / Cantarero, D. et al. | 2018
-
PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGALFerreira, C. / Andreozzi, V. / Vandewalle, B. / Félix, J. et al. | 2018
-
PHP86 - IMPORTANCE OF CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING FOR NON-LIFE-THREATENING DISEASESFunagoshi, M. / Murasawa, H. / Shiroiwa, T. / Saito, S. / Shimozuma, K. et al. | 2018
-
PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALYUrbinati, D. / Rova, A. / Cioni, L. et al. | 2018
-
PHP54 - DIRECTIVE 2004/18/EC: IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPEZegaoui, Y. / Sogokon, P. / Morrison, S. et al. | 2018
-
PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIESGuarga, L. / Fondevilla, E. / Pastor, M. / Roig, M. / Cirera, J. / Llop, C. / Alonso, E. / Obach, M. / Fontanet, M. / Gasol, M. et al. | 2018
-
PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAELWeil, C. / Chodick, G. / Shalev, V. / Demuth, D. / Petrakis, I. / Ben Baruch, O. / Tsukinovsky, S. / Yarden, A. et al. | 2018
-
PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5Annunziata, K. / Sternbach, N. / Carpinella, C.M. / Chapnick, J. / Patel, P. / McDonald, M. / McElwee, N. et al. | 2018
-
PDB111 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG DIABETES MELLITUS PATIENTS IN A NATIONAL HEALTH INSURANCE PROGRAMCheng, J. / Ku, H. / Huang, C. / Hsu, C. et al. | 2018
-
PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN: NATIONWIDE RETROSPECTIVE COHORT STUDYToll, A. / Eliasson, B. / Lebrec, J. / Karlsdotter, K. / Miftaraj, M. / Franzen, S. / Svensson, A. et al. | 2018
-
PDB102 - THERAPY ADJUSTMENT FOLLOWING DPP-4 INHIBITOR INITIATION IN T2DM PATIENTS WITH CREATININE CLEARANCE <50 ML/MIN: A RETROSPECTIVE COHORT STUDY USING DATA FROM UK GENERAL PRACTICESpanopoulos, D. / Barrett, B. / Busse, M. / Roman, T. / Poole, C. et al. | 2018
-
PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIESHanna, E. / Dussart, C. / Auquier, P. / Toumi, M. et al. | 2018
-
PHP309 - HTA CAPACITY BUILDING - OPPORTUNITIES AND CHALLENGES AS RESULT OF HTA INSTITUTIONS RESEARCHGeorgiev, S. / Yanakieva, A. / Velikov, S. et al. | 2018
-
PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESSNeri, M. / Hampson, G. / Towse, A. et al. | 2018
-
PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIESSidzhimova, D. / Benisheva, T. / Boncheva, E. / Trendafilova, P. / Kralimarkov, N. et al. | 2018
-
PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?Rémuzat, C. / François, C. / Toumi, M. et al. | 2018
-
PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALSLing, C. / Nuabor, W. / Lyall, M. / Stevenson, A. et al. | 2018
-
PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE USFiglar, H. / Arnold, M. / Wray, J. / Hoskins, N. / Fletcher-Louis, M. / Casanova, C. et al. | 2018
-
PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?Colasante, W. et al. | 2018
-
PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?Scheler, E. / Stratil, A. / Roxlau, T. / Bonduelle, D. et al. | 2018
-
PHP255 - EUROPEAN "REAL-WORLD" EVIDENCE FOR DRUGS AND DEVICES: 2017 LITERATURE REVIEWEDMordin, M. / Castro, C. / Buck, P.M. / Fernandez, M.M. / Hollis, K.A. / Ritchey, M.E. et al. | 2018
-
PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCEVasilescu, L. / Faller, M. / Allou, A. et al. | 2018
-
PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATEDAlthobaiti, H.A. / Alsheikh, M.Y. / Seoane-Vazquez, E. / Lewis, J. / Brown, L.M. et al. | 2018
-
PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS): CLARIFYING THE PREVIOUS CONFUSIONAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
-
PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK: IDEGLIRA VERSUS IGLARLIXIHvid, C. / Parekh, W. / Pöhlmann, J. / Hunt, B. et al. | 2018
-
PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTINGPrager, R. / Price, H. / Blüher, M. / Fernandes, J. / Møller, J.B. / Schultes, B. et al. | 2018
-
PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIAJanzic, A. / Locatelli, I. et al. | 2018
-
PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UKWickramasekera, N. / Howard, A. / Shackley, P. et al. | 2018
-
PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETESLage, M.J. / Bae, J. / Mody, R. / Botros, F.T. / Wu, J. / Boye, K. et al. | 2018
-
PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENTHickey, D.A. / Beecroft, S. et al. | 2018
-
PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIESAbdel Rida, N. / Mohamed Ibrahim, M.I. / Owusu, Y. / Babar, Z. et al. | 2018
-
PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTSLaven, A. / Nasert, S. / Katzfey, U. / Amelung, V. / Klemm, M. / Knoefler, M. / Mueller, H. / Rupprecht, C. / Unkrig, S. / Vrijens, B. et al. | 2018
-
PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILUREFerreira, C. / Vandewalle, B. / Félix, J. / Gomes, S.O. et al. | 2018
-
PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING: AN INTERRUPTED TIME SERIES ANALYSISSultanov, M. et al. | 2018
-
PCN272 - ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS: LENALIDOMIDE UTILISATION AND EXPENDITURE IN IRELANDMcCabe, L. / Moloney, D. / Barry, M. / Usher, C. / McCullagh, L. et al. | 2018
-
PCN269 - HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH TREATMENT IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) RELAPSED OR REFRACTORY (R/R) B-CELL PRECURSOR (BCP) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIESZhang, X. / Zhang, L. / Gijsen, M. / Cong, Z. et al. | 2018
-
PCN214 - IBRITUMOMAB TIUXETAN RADIOLABELLED WITH YTTRIUM CHLORIDE: 4 YEARS OF USE IN THE 37 PUBLIC HOSPITALS OF PARIS AND IN FRANCEGérard, C. / Therasse, C. / Cordonnier, A. / Degrassat-Théas, A. / Paubel, P. / Fusier, I. et al. | 2018
-
PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVALEriksson, I. / Wettermark, B. / Bergfeldt, K. et al. | 2018
-
PCN264 - ASSESSMENT OF TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN SPAIN FOLLOWING INITIAL PLATINUM THERAPY FOR RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)Parikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Sawyer, W. / Wang, H. et al. | 2018
-
PCN198 - AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)Robson, R.E. / Cranmer, H. / Huang, J. / Selby, R. / Lin, H.M. / Tolley, K. et al. | 2018
-
PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADALakhdari, K. / Young, K.C. / Holdgate, O. / Doan, J. et al. | 2018
-
PCN133 - THE SOCIETAL IMPACT OF OBINUTUZUMAB IN THE FIRST LINE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN GERMANYHofmann, S. / Ostwald, D.A. / Himmler, S. / Launonen, A. / Dünzinger, U. / Salmen, H. et al. | 2018
-
PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACKIncerti, D. / Shafrin, J. / Lakdawalla, D.N. / Zhao, L. / Linthicum, M. / Jansen, J.P. et al. | 2018
-
PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATESKearney, M. / Thokagevistk, K. / Boutmy, E. / Sherman, S. / Bharmal, M. et al. | 2018
-
PCN129 - TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMRosim, R.P. / Julian, G. / Mendes, A. / Ricco, M. / Fioratti, C.O. / Scaccabarozzi, L. et al. | 2018
-
PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAXCho, S.K. / Samp, J.C. / Keim, H. / Masaquel, A.S. / Johnson, S.J. / Parise, H. et al. | 2018
-
PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + USDe Cristofano, F. / Barling, H.D. / Bell, C. et al. | 2018
-
PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPANFukuda, H. / Ishida, H. / Sato, D. / Moriwaki, K. et al. | 2018
-
PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICOAlva, M.E. / Ortíz, M. / Flores, B. et al. | 2018
-
PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Morten, P. / Goyert, N. / Vieira, J. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN34 - PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC – A NETWORK META-ANALYSISFrederickson, A.M. / Arndorfer, S. / Lorenzi, M. / Insinga, R. / Chandwani, S. / Burke, T. et al. | 2018
-
PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OSBaculea, S. / Horsburgh, S. / Chadda, S. / Nelson, L. / LeReun, C. et al. | 2018
-
PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCERKirsanova, O. / Sukhorukikh, O. et al. | 2018
-
PCV45 - BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSIONTolordava, G. / Yagudina, R. / Arinina, E. et al. | 2018
-
PCV23 - TIME TO TREATMENT INTENSIFICATION IN NEW STATIN USERSMachado-Duque, M. / Gaviria-Mendoza, A. / Machado-Alba, J. et al. | 2018
-
PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.Azizoddin, D. / Rynar, L. / Molokie, R. / Hauser, J. / Payvar, S. / Martin, J. et al. | 2018
-
PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTAFathollah-Nejad, R. / Luhnen, M. / Rehrmann, M. et al. | 2018
-
PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEINGable, J. / Ayer, D. / Girvan, A. / Bowman, L. / Abada, P. / Ervin, C. / Evans, E. / Cella, D. et al. | 2018
-
PCP8 - BENELUXA INITIATIVE: WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCN361 - HEALTH ECONOMIC VALUE PROPOSITIONS FOR SUBCUTANEOUS TRASTUZUMAB AND THEIR TRANSFERABILITY TO CENTRAL-EASTERN EUROPEAN COUNTRIESInotai, A. / Ágh, T. / Karpenko, A.W. / Zemplényi, A. / Kaló, Z. et al. | 2018
-
PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS: A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.Khan, S. / Teale, C.W. / Heupel, M. / Czira, A. et al. | 2018
-
PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIAAlcalá, H.E. / Maxwell, G.L. / Keim-Malpass, J. / Mitchell, E. / Balkrishnan, R. et al. | 2018
-
PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN'S LYMPHOMAMierzynska, J. / Taye, M. / Pe, M. / Coens, C. / Martinelli, F. / Flechtner, H. / Meijnders, P. / Lugtenburg, P.J. / Shepherd, L. / Hertzberg, M. et al. | 2018
-
PCN314 - HEALTH-TECHNOLOGY ASSESSMENTS IN ONCOLOGY: RESULTS OF A REVIEW OF DECISIONS IN GERMANYGottschalk, F. / Mueller, S. / Wilke, T. et al. | 2018
-
PCN302 - IS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY INDICATIONS TOO POSITIVE IN ITS ASSESSMENT OF CANCER DRUGS IN ENGLAND?Chunara, F. / Foxon, G. / Craddy, P. et al. | 2018
-
DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONSSmith, W. / Orlowski, A. / Itrakjy, A. / Porter, A. / Willis, T. et al. | 2018
-
CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCERHolleman, M.S. / Al, M.J. / Uyl-de Groot, C.A. et al. | 2018
-
AD2 - A FULLY INTEGRATED CLINICAL TRIAL LIKE SYSTEM TO GUARANTEE PERSISTENCE ON PLANNED HEPATITIS C TREATMENT: EVIDENCE FROM THE REAL-WORLDGomes, I. / Figueira, A. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Granjeia, R. / Andreozzi, V. / Félix, J. et al. | 2018
-
PHP367 - PROFESSIONALS' PERSPECTIVE OF FACTORS INFLUENCING THE DEVELOPMENT OF A SUCCESSFUL PHARMACEUTICAL PRODUCT. THEMATIC ANALYSISFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
-
PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTSAl Rabayah, A.A. / Salmany, S. / Al Froukh, R. / AL Rayyan, M. / Al Najjar, B. / Nazer, L. et al. | 2018
-
PIN8 - COMPARATIVE EFFICACY OF FIDAXOMICIN, VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION: A NETWORK META-ANALYSISOkumura, H. / Fukushima, A. / Taieb, V. / Shoji, S. / English, M. et al. | 2018
-
PIH22 - ECONOMIC IMPACT OF DONOR HUMAN MILK VERSUS FORMULA FOR VERY LOW BIRTH WEIGHT INFANTS IN THE NEONATAL INTENSIVE CARE UNITJohnson, T.J. / Sulo, K. / Meier, P.P. / Patel, A.P. et al. | 2018
-
PIH13 - ABIRATERONE: A SINGLE-CENTRE EXPERIENCERaposo, J.P. / Barros, C.T. / Caetano, F.R. et al. | 2018
-
PHP207 - ASSESSMENT OF PHARMACIST MEDICATION CONSULTATION IN COMMUNITY PHARMACIES LOCATED IN TEHRANIzadpanah, F. / Akbari Sari, A. / Zargaran, M. / Ashrafian rahaghi, M.M. et al. | 2018
-
PHP138 - CHANGES IN THE NUMBER OF MIDWIVES IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Boncz, I. / Ágoston, I. / Horváth, L. / Gratz, B. / Németh, N. / Horváthné Kívés, Z. / Endrei, D. et al. | 2018
-
PHP106 - IMPACT OF ACCESS RESTRICTION ON USE OF SHORT-ACTING PRESCRIPTION OPIOIDS IN A US HEALTH PLANShcherbakova, N. / Tereso, G. et al. | 2018
-
PHP101 - SOCIO-ECONOMIC AND SOCIO-DEMOGRAPHIC DRIVERS INFLUENCING PREVALENCE OF ANTIBIOTIC USE: AN ANALYSIS IN SOUTHERN ITALY SETTINGRusso, V. / Mucherino, S. / Guerriero, F. / Orlando, V. et al. | 2018
-
PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018Lidonnici, D. / Lanati, E.P. / Niedecker, S. / Isernia, M. et al. | 2018
-
PHP81 - COMPARISON OF SELECTED DRUGS PRICES IN EU COUNTRIESBucek Psenkova, M. / Mackovicova, S. et al. | 2018
-
PHP70 - COUNTRY-SPECIFIC DRIVERS AND BARRIERS FOR MARKET ACCESS OF E-HEALTH SOLUTIONSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP46 - IS EUROPE WAKING UP TO BIOPHARMACEUTICAL INNOVATION? PERSPECTIVES FROM EXPERT APPRAISAL OF RECENT ORPHAN DISEASE THERAPY VALUE ASSESSMENTS AND THEIR SUPPORTING LEGAL / POLICY FRAMEWORKSLeffell, D. / O'Rourke, M. / McGahan, S. / Pikus, J. / Duttagupta, S. et al. | 2018
-
PHP11 - HOW TO RESOLVE ISSUES EXPERIENCED BY PATIENTS IN EARLY PHASE DEVELOPMENT OF PHARMACEUTICAL PRODUCTSFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
-
PHP20 - EUROPE-WIDE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: EPIDEMIOLOGY AND DISEASE BURDENPalmer, T. / Collings, H. / Tavella, F. et al. | 2018
-
PGI36 - OUT-OF-POCKET AND CATASTROPHIC HEALTH EXPENDITURES AMONG HEPATITIS C PATIENTS: RESULTS FROM A MIDDLE-INCOME COUNTRYAzzeri, A. / Shabaruddin, F.H. / Jaafar, H. / Mohamed, R. / Dahlui, M. et al. | 2018
-
PGI5 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER COLORECTAL SURGERYLeaper, D.J. / Holy, C.E. / Ghosh, E. / Chen, B.P. / Edmiston, C.E. et al. | 2018
-
PDB117 - CHANGES IN PATIENT REPORTED OUTCOMES, ATTITUDES AND HEALTH BEHAVIORS IN 606 PEOPLE WITH DIABETES FOLLOWING 2 MONTHS USE OF THE DRUGSTARS HEALTH APPSkovlund, S.E. / Moeldrup, C. et al. | 2018
-
PDB115 - IS USING MMAS-8 ALONE RELIABLE AND NONBIAS WHEN MEASURING MEDICATION ADHERENCE?Mohamed Ibrahim, M.I. / Arafat, Y. / Awaisu, A. / Owusu, Y. / AlHafiz, M. / Yousif, A. et al. | 2018
-
PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPYWilson, M. / Lucas, A. et al. | 2018
-
PHP351 - RISK-SHARING OR RISK-SHIFTING? THE EVOLUTION OF PAYER/INDUSTRY AGREEMENTS IN THE ANNUAL PROCESS OF UPDATING THE NATIONAL LIST OF HEALTH SERVICES IN ISRAELTriki, N. / Ash, N. / Porath, A. / Birnbaum, Y. / Greenberg, D. / Hammerman, A. et al. | 2018
-
PHP328 - REAL-WORLD-DATA AND REAL-WORLD-EVIDENCE STATE OF ART FROM A LITERATURE REVIEW PERSPECTIVEGreco, T. / Rizzo, E. / Buseghin, G. / Murphy, J. / Pinciroli, M. / Mordenti, G. et al. | 2018
-
PHP317 - IDENTIFYING THE CHANGES REQUIRED IN HEALTH TECHNOLOGY ASSESSMENT SYSTEMS IF OUTCOMES ARE TO BE OPTIMIZED IN A DIGITAL WORLD WHERE PERSONALIZED DATA AND PRECISION MEDICINE COLLIDETeale, C.W. / Khan, S. / Heupel, M. et al. | 2018
-
PHP305 - CONSIDERING CHILDREN ALONGSIDE ADULTS IN NICE TECHNOLOGY APPRAISALS AND HIGHLY SPECIALISED TECHNOLOGIES EVALUATIONSMikudina, B. / Robertson, J. / Upadhyaya, S. et al. | 2018
-
PHP304 - INTRODUCTION OF EBM IN MEDICAL PROFESSIONALS' EDUCATION IN BULGARIA, IN ASSOCIATION WITH THE HTA PROCESS - A PILOT STUDYLeventi, N. / Yanakieva, A. / Stoimenova, A. et al. | 2018
-
PHP298 - ON THE RIGHT TRACK? EXAMINING NICE'S FAST-TRACK APPRAISAL PROCESSCrutwell, J.R. / Miller, R. / Ioannou, P. / Payne, R. / Fountain, D. et al. | 2018
-
PHP299 - THREE YEARS OF SINATSFélix, A.R. / Ferreira, C. / Félix, J. / Vandewalle, B. et al. | 2018
-
PHP237 - OVERVIEW OF GERMAN AMNOG DOSSIERS WITH PRICE ANALYSIS BEFORE AND AFTER EARLY BENEFIT ASSESSMENTBonduelle, D. / Batscheider, A. / Tremmel, M. / Antoni, B. / Bocuk, D. / Roxlau, T. / Mihaylova, E. et al. | 2018
-
PHP220 - OLD DRUGS TURNED NEW FOR ULTRA ORPHAN DISEASE: A CHALLENGE FOR PAYERS OR FOR THE INDUSTRY?Van Tendeloo, M. / Clerinx, C. et al. | 2018
-
PHP215 - DANISH MEDICINE COUNCIL PROCESS OF ASSESSING NEW HOSPITAL MEDICINES– FIRST YEAR OF IMPLEMENTATIONDibbern, T. / Medin, E. et al. | 2018
-
PDB78 - ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTINGMoshel, S. / Hirsch Vexberg, M. / Shavit, O. / Toledano, Y. et al. | 2018
-
PDB90 - ASSOCIATION BETWEEN SULFONYLUREA (SU) TREATMENT AND TRAFFIC ACCIDENTS IN DENMARKBerger, J. / Elbrond, B. / Lassota, N. / Kjellberg, J. / Ibsen, R. / Rungby, J. et al. | 2018
-
PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALSLamotte, M. / Ramos, M. / Salem, A. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Foos, V. et al. | 2018
-
PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIALKaku, K. / Haneda, M. / Sakamaki, H. / Yasui, A. / Murata, T. / Ustyugova, A.V. / Chin, R. / Hirase, T. / Shibahara, T. / Hayashi, N. et al. | 2018
-
PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINADeng, H. / Yang, F. / Du, X. / Xuan, J. et al. | 2018
-
PDB27 - CLINICAL INERTIA IN RELATION TO BARRIERS TO PROGRESSION TO INJECTABLE THERAPY IN TYPE 2 DIABETES: A SYSTEMATIC LITERATURE REVIEWBain, S. / Hansen, B.B. / Doran, S. / Goode, B. et al. | 2018
-
PCV142 - ADHERENCE TO ORAL ANTICOAGULATION TREATMENT IN ATRIAL FIBRILLATION AND THE IMPACT OF PATIENT SATISFACTIONMueller, S. / Meinecke, A. / Buchwald, S. / Heideman, L. / Eriksson, D. / Wilke, T. et al. | 2018
-
PCV118 - FACTORS DETERMINING SELECTION OF APPROPRIATE PATIENTS FOR PCSK9 INHIBITORS IN EUROPEAN CLINICAL PRACTICETai, M. / Qian, Y. / Coll Crespo, B. / McKendrick, J. / Wieffer, H. / Cerezo Olmos, C. et al. | 2018
-
PCV111 - CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM PRESCRIBED ANTICOAGULANTS IN GERMANYSchmedt, N. / Heuer, D. / Basic, E. / Häckl, D. / Jenkins, A. et al. | 2018
-
PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECEStafylas, P. / Karaiskou, M. / Arzoumanidou, D. / Kolevris, N. / Kotsanis, A. / Chatzopoulos, S. / Stephens, S. / Schoeman, O. / Briere, J. / Kanakakis, I. et al. | 2018
-
PCN262 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH LUNG CANCER IN SPAINGómez-Navarro, V. / Callejo-Velasco, D. / De Prado, A. / Á, Baltasar-Sanchez / Canal-Díaz, N. / Barrull, C. et al. | 2018
-
PCN249 - CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) AND DRIVERS OF ANTIEMETIC PRESCRIBING: RESULTS OF A QUALITATIVE IN-PRACTICE STUDY OF CLINICIANS FROM VARIOUS SETTINGSLeBlanc, T.W. / D'Agostino, P. / Ruffo, P. / Turini, M. / Harmon, A.L. / Ortendahl, J.D. et al. | 2018
-
PCN224 - TOWARDS CLINICAL ADOPTION OF REPURPOSED DRUGS IN ONCOLOGY: OVERCOMING REGULATORY AND MARKET ACCESS BARRIERS IN EUROPEVerbaanderd, C. / Rooman, I. / Meheus, L. / Huys, I. et al. | 2018
-
PCN222 - TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILISATION (HCRU) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN CANADA AND EUROPEJaffe, D.H. / Gill, S. / DeCongelio, M. / Dubell, A. / Stetson, J. / Wisniewski, T. / Thompson, G.J. et al. | 2018
-
PCN213 - FINANCING EXPENSIVE ANTICANCER DRUGS IN HOSPITALS: TOWARDS TRANSPARENCY TO IMPROVE PATIENT ACCESSSilva, M.L. / Aulois-Griot, M. et al. | 2018
-
PCN150 - COST-EFFECTIVENESS ANALYSIS OF PHARMACOKINETIC-GUIDED (PK) 5-FLUOROURACIL (5-FU) DOSING WHEN COMBINED WITH LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) CHEMOTHERAPY FOR ADVANCED PANCREAS CANCEREgues, A. / Aldaz, A. / Rodriguez, J. / Delgado, L. / Ortega, A. et al. | 2018
-
PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIADjambazov, S. / Slavchev, G. / Encheva-Malinova, M. / Varbanova, V. / Velchev, M. / Raduilov, B. / Vekov, T. et al. | 2018
-
PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUMMoeremans, K. / Van Bellinghen, L. / De Celle, T. / Quintens, B. / Paracha, N. et al. | 2018
-
PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGALSoares, V. / Orfanos, P. / Pereira, C. et al. | 2018
-
PCN92 - THE EVALUATION OF THE ECONOMIC EFFICIENCY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RUSSIAN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMADerkach, E.V. / Abashin, S.Y. et al. | 2018
-
PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIADjambazov, S. / Slavchev, G. / Encheva-Malinova, M. / Pavlova, Y. / Varbanova, V. / Velchev, M. / Vekov, T. et al. | 2018
-
PCN74 - A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCERWalter, E. / Lazic-Peric, A. et al. | 2018
-
PCN55 - TYPE-SPECIFIC DATA ON HUMAN PAPILLOMAVIRUS INFECTION IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA IN THE ASIA-PACIFIC REGIONBennetts, L. / Wagner, M. / Bagdley, D. / Kothari, S. / Morais, E. et al. | 2018
-
PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAINCiruelos, E. / Alba, E. / Lopez, R. / Lluch, A. / Martin, M. / Arroyo, I. / Navarro, B. / Carcedo, D. / Colomer, R. / Albanell, J. et al. | 2018
-
PCN48 - REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYCizova, D. / Gottschalk, F. / Mueller, S. / Myers, D. / Wilke, T. et al. | 2018
-
PCN42 - EFFICACY OF THIRD LINE TYROSINE KINASE INHIBITORS FOR TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOURS: SYSTEMATIC REVIEW AND META-ANALYSISShohet, S. et al. | 2018
-
PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPANIkeda, S. / Kudo, M. / Izumi, N. / Kaneko, S. / Kobayashi, M. / Azuma, M. / Copher, R. / Virabhak, S. / Mitchell, D. / Meier, G. et al. | 2018
-
PCN8 - SEVERITY OF BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES AND NOT WITH INSULIN TREATMENTOverbeek, J.A. / van Herk-Sukel, M.P. / Vissers, P.A. / van der Heijden, A.A. / Bronsveld, H.K. / Herings, R.M. / Schmidt, M.K. / Nijpels, G. et al. | 2018
-
PP1 - CONSIDERATIONS FOR USING A WEB-BASED SYSTEM TO COLLECT PATIENT-REPORTED OUTCOME (PRO) DATATritton, T. / Panter, C. / Johnson, C. / Bradley, H. / Tinsley, K. / Bennett, B. et al. | 2018
-
PCV48 - TOTAL ANNUAL HEALTHCARE COSTS OF HEART FAILURE BETWEEN 2005 AND 2014: A RETROSPECTIVE, POPULATION-BASED STUDY IN SWEDENBoman, K. / Lindmark, K. / Stålhammar, J. / Olofsson, M. / Costa-Scharplatz, M. / Fonseca, A.F. / Bruce Wirta, S. / Castelo-branco, A. / Törnblom, M. / Wikström, G. et al. | 2018
-
PCV16 - A SYSTEMATIC REVIEW ON THE EFFICACY OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF)Agrawal, R. / Ahuja, A. / Thakur, L. / Natani, H. / Cristino, J. / Croft, D. / Gielen, V. et al. | 2018
-
PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECEStafylas, P. / Karaiskou, M. / Arzoumanidou, D. / Kolevris, N. / Kotsanis, A. / Chatzopoulos, S. / Stephens, S. / Schoeman, O. / Briere, J. / Kanakakis, I. et al. | 2018
-
PCP62 - MARKET ACCESS UNDER AGILE CIRCUMSTANCESSchönermark, M. / Priese, K. / Kielhorn, H. et al. | 2018
-
PCP49 - EXPLORING THE SENSITIVITY TO CHANGE OF THE SAMANTA QUESTIONNAIRE IN HEAVY MENSTRUAL BLEEDING: THE SAMIRA STUDYRius, J. / Pujol, P. / Carrasco, M. / Catafal, G. / Calaf, J. et al. | 2018
-
PCP51 - OBSERVATIONAL STUDIES COLLECTING PATIENT PREFERENCES AND EXPERIENCES: REGULATORY DIFFERENCES ACROSS COUNTRIES IN EUROPESluga-O'Callaghan, M. / Ansquer, V. / Frugier, G. / Mai, C. et al. | 2018
-
PCP32 - INTRODUCTION OF TRIAL-BASED ECONOMIC EVALUATIONS IN UKRAINE: ANALYSIS OF PERSPECTIVES AND BARRIESDobrova, V. / Ratushna, K. / Zupanets, K. et al. | 2018
-
PCN367 - HEALTH-RELATED QUALITY OF LIFE ON CÁNCER PATIENTS IN COLOMBIARomero, M. / Gallo, D. / Garzon, A. / Chavez, R. et al. | 2018
-
PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITYMartinez-Herrera, B. / Balderas-Peña, L. / Sat-Muñoz, D. / Trujillo-Hernández, B. / Gonzalez-Barba, F. / Solórzano-Meléndez, A. / López-Almaraz, L.M. / Bayardo-López, L.H. / Alvarado-Zermeño, A. / Salazar-Páramo, M. et al. | 2018
-
PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Higson, O. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
-
PCN338 - THE EVOLUTION OF TREATMENT ALGORITHMS IN NON-SMALL-CELL LUNG CANCER: IMPLICATIONS FOR REIMBURSEMENTS IN ENGLANDMiller, R. / Crutwell, J.R. / Shaw, C. / Lawrence, H. / Fountain, D. et al. | 2018
-
PCN282 - CANCER DRUGS FUND (CDF) IN THE UNITED KINGDOM: A 2-YEAR ANALYSISCalderwood, S. / de Rome, R. / Rowbottom, R. / Matar, M. et al. | 2018
-
CP3 - PATIENTS-INTERVENTION-COMPARATORS-OUTCOMES-SETTINGS-TIME-EFFECTS-SENSITIVITY (PICOSTEPS): REPRESENTING EVIDENCE-BASED HEALTH ECONOMIC EVALUATIONS (EBHEE) IN THE ORDER OF IMPORTANCESoini, E. et al. | 2018
-
CE2 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAINBenjamin, N. / Huerta, A. / Biswas, C. / Schroeder, M. / Whalen, J. / Izquierdo, Alonso J.L. / Soler Cataluña, J.J. / Riesco Miranda, J.A. / Martin, A. / Atienza, L. et al. | 2018
-
PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNITAl Rabayah, A.A. / Salmany, S. / Al Froukh, R. / AL Rayyan, M. / Al Najjar, B. / Nazer, L. et al. | 2018
-
PCP70 - REGENERATIVE MEDICINE: A PROPOSED CLASSIFICATION FOR HEOR BASED ON THERAPEUTIC STRATEGY AND TECHNOLOGY TYPEPurser, M. / Mladsi, D.M. et al. | 2018
-
PIH40 - THE HEALTH LITERACY OF IRANIAN PARENTS: A SURVEY IN TEHRAN CAPITAL CITYYousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDYAl-Rashidi, A. / Al-Subaie, S.A. / Farooqui, M. et al. | 2018
-
PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIAAlmogbel, Y. / AlQussiar, J. et al. | 2018
-
PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICSSharif, Z. / Yousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIESAlmasi, T. / Fasseeh, A.N. / Elezbawy, B. / George, M. / Abouelmaged, E. / Arnaiz, F. / Abaza, S.A. / Nagy, B. / Kaló, Z. et al. | 2018
-
PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES: VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALSShimizu, S. / Shinjo, D. / Sakata, N. / Ishikawa, K.B. / Fushimi, K. et al. | 2018
-
PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIAWondimu, A. / Postma, M.J. et al. | 2018
-
PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLANDAtikeler, K. / Goettsch, W. / Baran, A. / Gaitova, K. / Bayar, B. / Czech, M. / Leufkens, H.G. et al. | 2018
-
PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANYBot, D. / Linstaedt, J. / Ecker, T. et al. | 2018
-
PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCEPetri, C. / Holscher, E. / Borget, I. / Bertin, L. et al. | 2018
-
PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANYMathes, J. / Höer, A. et al. | 2018
-
PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?Pónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
-
PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELANDGorry, C. / Hanevy, A. / O'Leary, A. / Tilson, L. / Barry, M. et al. | 2018
-
PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTINGO'Brien, G.L. / Carroll, D.G. / Walshe, V. / Mulcahy, M. / Courtney, G. / O'Mahony, C. / Byrne, S. et al. | 2018
-
PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
-
PGI29 - GENDER DIFFERENCES IN CLINICAL PROFILE AND HEALTHCARE UTILIZATION OF NON ALCOHOLIC FATTY LIVER PATIENTSGoldshtein, I. / Chodick, G. / Shibolet, O. et al. | 2018
-
PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIESNorrbacka, K. / Divino, V. / Boye, K. / Lebrec, J. / Dekoven, M. et al. | 2018
-
PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE : THE QUESTIONNAIRE " TOP SCORE "Michiels, Y. / Bugnon, O. / Vergez, G. / Allaert, F. et al. | 2018
-
PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPTAmin, M. / Abotaleb, A. et al. | 2018
-
PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES: DOES REALITY ALIGN WITH INTENT?Desai, B. / Oehrlein, E. / Ganser, T.R. / Ngo, M. / Perfetto, E.M. et al. | 2018
-
PHP322 - REAL-WORLD DATA : WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?Petitjean, A. / Roze, S. et al. | 2018
-
PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)Palacios, L. / De Cock, E. et al. | 2018
-
PHP332 - INTRODUCTION OF MOBILE HEALTH TECHNOLOGY AT THE PRIMARY HEALTHCARE LEVEL IN MONGOLIAChimeddamba, O. et al. | 2018
-
PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?Siering, U. / Özdemir, D. / Thys, S. / Altenhofen, L. / Mischke, C. et al. | 2018
-
PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALSNg, T. / Ziomek, J. / Delaitre-Bonnin, C. / Bending, M.W. et al. | 2018
-
PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATIONBaker, T. / Marinoni, G. / Houslay, D. / Tao, T. / Garbaz, O. / Malhotra, S. et al. | 2018
-
PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANYSchikowski, M. / Gibson, L. / Mrosowsky, T. / Schönermark, M. et al. | 2018
-
PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FARRothwell, S. / Macaulay, R. et al. | 2018
-
PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALSGriffiths, E.A. / Hendrich, J. et al. | 2018
-
PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UKWebster, S. / Hau, N. / Ustyugova, A.V. / Kansal, A.R. / Reifsnider, O. et al. | 2018
-
PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM: A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCENguyen, T.T. et al. | 2018
-
PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETESMelzer Cohen, C. / Chodick, G. / Nystrup Husemoen, L.L. / Rhee, N.A. / Shalev, V. / Karasik, A. et al. | 2018
-
PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACHZhou, F.L. / Watada, H. / Tajima, Y. / Berthelot, M. / Kang, D. / Esnault, C. / Shuto, Y. / Maegawa, H. / Koya, D. et al. | 2018
-
PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETESHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTSLavikainen, P.T. / Hartikainen, J. / Miettinen, H. / Viljakainen, M. / Martikainen, J.A. / Tolppanen, A. / Roine, R.P. et al. | 2018
-
PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCELanitis, T. / Bregman, B. / Maunoury, F. / Prawitz, T. / Gaudin, A. / Cotté, F. et al. | 2018
-
PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE: A SYSTEMATIC REVIEWKumar, S. / Loh, F.E. et al. | 2018
-
PCN223 - WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?Huguet, M. / Joutard, X. / Ray-Coquard, I. / Perrier, L. et al. | 2018
-
PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEWCholasamudram, S. / Yenamandra, J. / Jindal, R. / Cristino, J. et al. | 2018
-
PCN239 - NICE AND THE CANCER DRUGS FUND: APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLANDEdwards, H.K. / Kent, E. / Landells, L.J. et al. | 2018
-
PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH: WHAT CAN BE LEARNED?Bouee Benhamiche, E. / Le Bihan Benjamin, C. / Rocchi, M. / Negellen, S. / Bousquet, P.J. et al. | 2018
-
PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANYEscalada, J. / Bonnet, F. / Wu, J. / Bonnemaire, M. / Gupta, S. / Cambron-Mellot, M.J. / Nicholls, C. / Müller-Wieland, D. et al. | 2018
-
PCN217 - KEEPING UP WITH THE COMPARATORS: TRENDS IN TARGETED CANCER THERAPIES BECOMING RIGHT COMPARATORS FOR PAYERSWijnands, T. / Strydom, M. / Spinas, N. / van Engen, A. et al. | 2018
-
PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTSBellone, M. / Pradelli, L. / Masetti, L. / Recchia, A. / Orfanos, P. et al. | 2018
-
PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIRNuñez Alfonsel, J. / Hidalgo, A. / Ielpo, B. / Quijano, Y. / Vicente, E. et al. | 2018
-
PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?Ramon, A. / Paladio, N. / Male, N. et al. | 2018
-
PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGALGuerreiro, R. / Miguel L, Silva / Costa, J. / Paquete, A.T. / Alarcão, J. / Fiorentino, F. / Borges, M. et al. | 2018
-
PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBECPettigrew, M. / Garces, K. et al. | 2018
-
PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMASiskou, O. / Terpos, E. / Galanis, P. / Vasilakopoulos, T. / Tsirigotis, P. / Batsis, I. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIAWalter, E. / Lazic-Peric, A. / Schalle, K. / Voit, M. et al. | 2018
-
PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINAZhang, Y. / Samuelsen, C.H. / Griebsch, I. / Yao, Z. et al. | 2018
-
PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYCizova, D. / Gottschalk, F. / Mueller, S. / Myers, D. / Wilke, T. et al. | 2018
-
PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHINGGurskyte, L. / Muresan, B. / Kulakova, M. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA: A NATIONWIDE SURVEYWang, P. / Li, C. et al. | 2018
-
PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATESDaSilva, C. / Noone, J.M. / Wriede, V. et al. | 2018
-
QL1 - VALIDATION OF PROMIS PREFERENCE SCORE (PROPR) IN GERMAN PATIENTS WITH RHEUMATOLOGICAL CONDITIONSKlapproth, C.P. / Obbarius, A. / Merbach, M. / Rose, M. / Fischer, F. et al. | 2018
-
PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATIONRyazhenov, V.V. / Gorokhova, S.G. / Gorokhov, V. et al. | 2018
-
PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES: A NATIONWIDE POPULATION-BASED COHORT STUDYYun, J.E. et al. | 2018
-
PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANYWachter, R. / Klebs, S. / Balas, B. / Kap, E.J. / Engelhard, J. / Schlienger, R. / Fonseca, A.F. / Proenca, C.C. / Bruce Wirta, S. et al. | 2018
-
PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCECohen, S. / Paubel, P. / Monchecourt, F. et al. | 2018
-
PCP69 - APPLICATION DECREE OF JARDE LAW: EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCEGuillemot, J. / Syed, I.A. / Jamet, N. et al. | 2018
-
PCP37 - THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIAPaveliu, M.S. / Radu, P. et al. | 2018
-
PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCERPakai, A. / Istlstekker, I. / Vajda, R. / Csákvári, T. / Váradyné Horváth, Á. / Póhr, K. / Fusz, K. / Boncz, I. / Oláh, A. et al. | 2018
-
PCN359 - COMPARISON OF INSTITUTIONAL AND HOME HOSPICE CAREDeleróza, A. / Fusz, K. / Pusztai, D. / Csákvári, T. / Váradyné Horváth, Á. / Á, Müller / Boncz, I. / Oláh, A. et al. | 2018
-
PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SETLatimer, N.R. et al. | 2018
-
PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?Walsh, S. / Liu, L.W. / Macaulay, R. et al. | 2018
-
PCN289 - HOW ACCELARATED IS PATIENTS' ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG'S FUND IN ENGLAND?Bates, B.E. / Tsoumani, E. et al. | 2018
-
PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIESAnjo, J. / Rider, A. / Bailey, A. / Gaudig, M. et al. | 2018
-
PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREAK.I.M., T. et al. | 2018
-
AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PCN339 - SPEAR-BLADDER (STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER): TIMING OF TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER IN THE COMMUNITY ONCOLOGY SETTING IN THE UNITED STATESDoshi, G. / Bhanegaonkar, A. / Bharmal, M. / Phatak, H. / Boyd, M. / Aguilar, K.M. / Kearney, M. et al. | 2018
-
CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTIONDong, O. / Lee, C.R. / Wheeler, S.B. / Voora, D. / Dusetzina, S.B. / Wiltshire, T. et al. | 2018
-
AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018)Lidonnici, D. / Lanati, E.P. / Niedecker, S. / Isernia, M. / Ronco, V. et al. | 2018
-
CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALSWang, S.V. / Schneeweiss, S. / Gagne, J.J. / Evers, T. / Gerlinger, C. / Desai, R. / Najafzadeh, M. et al. | 2018
-
PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PHP181 - HEALTH TECHNOLOGY ASSESSMENT OF ONCOLOGY THERAPIES IN SPAIN AND ITALY: KEY METRICS AND CONSIDERATIONSPrivolnev, Y. / Moore, R. / Sharma, K. et al. | 2018
-
PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITYEspinoza, S. / Tafur, H. et al. | 2018
-
PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICAMartin de Bustamante, M. / Alfonso, R. / Boers Trilles, V. / Guarin, D.F. et al. | 2018
-
PHP175 - EVOLUTION OF THE HEALTHCARE EXPENDITURES BY SERVICES IN HUNGARY BETWEEN 2010 AND 2015Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Ágoston, I. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE: AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINESPiniazhko, O. / Zaliska, O. / Ilyk, R. et al. | 2018
-
PHP168 - TRUMP'S PLANS TO REDUCE DRUG PRICES: FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRSTDabbous, M. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP157 - APETITE FOR ON PATENTS: COST OF PRESCRIBING SWITCHING IN GREECEManias, N.G. / Papadopoulos, K. / Stefanidou, Z. / Ollandezos, M. et al. | 2018
-
PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPTElMordy, B. / Fouad, S. / Elsisi, G.H. / Elmahdawy, M.D. et al. | 2018
-
PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP135 - CHANGES IN THE NUMBER OF DENTISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP120 - WHAT DO WE STAND TO LOSE? THE PROPORTION OF US-OWNED PHARMACEUTICALS ON AUSTRALIA'S PHARMACEUTICAL BENEFITS SCHEMEWeston, A. / Taylor, C. / Standfield, L. et al. | 2018
-
PHP115 - COMPARATIVE ANALYSIS OF THE MARKET PENETRATION OF PERSONALISED MEDICINE DRUGS UNDER THE CONDITIONS OF AMNOGFischer, T. / Bonduelle, D. / Antoni, B. et al. | 2018
-
PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVOHenic, H. / Music, E. / Mackic, M. / Hamzic, A. / Sofic, E. / Smailbegovic, E. / Čatić, T. / Jusufović, R. et al. | 2018
-
PHP87 - COULD THE FRENCH COHORT ATU PROGRAM BE THE MODEL EUROPE NEEDS TO HARMONIZE COMPASSIONATE USE PROGRAMS?Rivière, P. / Houzelot, D. / de Paz, B. / Salvignol, O. et al. | 2018
-
PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPEMak, C. / Marshall, J.D. et al. | 2018
-
PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASESKIM, H.R. / Crawford, B. et al. | 2018
-
PGI45 - RELIABILITY AND VALIDITY OF A NEW PATIENT-REPORTED OUTCOME FOR GASTROPARESISCheng, R. / Barnes, C. / Zhou, K. / Morris, S. / Goyal, A. / Cole, J.C. et al. | 2018
-
PDB135 - THE BURDEN OF DIABETES MELLITUS IN TAIWAN BASED ON PATIENT-REPORTED OUTCOMESFang, H. / Chen, C. / Lin, H. / Tang, C. et al. | 2018
-
PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)Debroucker, F. / Delporte, L. / Ullmann, E. et al. | 2018
-
PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET: OPPORTUNITIES FOR REFORMGoodman, C. / Villarivera, C. / Gregor, K.J. / van Bavel, J. et al. | 2018
-
PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING: A SYSTEMATIC LITERATURE REVIEWJaafer, N. / Biernikiewicz, M. / Toumi, M. et al. | 2018
-
PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIABhat, B. / Dharmagadda, S. / Udupa, N. et al. | 2018
-
PHP241 - INSIGHTS FROM PREVIOUS ATMP ASSESSMENTS IN THE UNITED KINGDOM, GERMANY AND FRANCE FOR FUTURE CAR-T REVIEWSSchuurman, S.M. / Poeton, A.K. / Delaitre-Bonnin, C. et al. | 2018
-
PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Rebelo de Sousa, C. / Tripathi, S. et al. | 2018
-
PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017Bezdenezhnykh, T. / Omelyanovskiy, V. / Avxentyeva, M. / Sura, M. et al. | 2018
-
PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARYNémeth, T. / Tabák, Á / Bán, A. / Bacskai, M. / Tarcsa, M. et al. | 2018
-
PDB23 - THE CLINICAL GAP BETWEEN THE GUIDELINES AND PRACTICE OF STATINS PRESCRIBING AMONG DIABETIC PATIENTSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWSOrigasa, H. / Yotsutani, N. et al. | 2018
-
PDB51 - RESULTS OF THE COSMODIA STUDY: ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN SPAINMata-Cases, M. / Mahon, J. / Mauricio, D. / Franch-Nadal, J. / Real, J. / Hex, N. et al. | 2018
-
PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOMReifsnider, O. / Kansal, A. / Franke, J. / Lee, J. / George, J.T. / Brueckmann, M. / Kaspers, S. / Brand, S. / Ustyugova, A. / Linden, S. et al. | 2018
-
PDB28 - TYPE 2 DIABETES: CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Baudot, F. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREAChae, I. / Cha, J. / Kim, Y. et al. | 2018
-
PDB1 - ACUTE RENAL OUTCOMES WITH SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS- REAL WORLD DATA ANALYSISMelzer Cohen, C. / Cahn, A. / Pollack, R. / Shalev, V. / Chodick, G. et al. | 2018
-
PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS: AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALEWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PCV110 - TREATMENT WITH FREE TRIPLE COMBINATION THERAPY OF ATORVASTATIN, PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN PATIENTS WITH HYPERTENSION: A REAL-WORLD POPULATION STUDY IN ITALY.Perrone, V. / Veronesi, C. / Degli Esposti, L. et al. | 2018
-
PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATIONXie, L. / Sun, X. / Mallampati, R. / Wang, Y. / Yuce, H. / Baser, O. et al. | 2018
-
PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC): RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIESKumar, J. / Patel, R. / Aggarwal, P. / Adler, B.N. / Gupta, J. et al. | 2018
-
PCN194 - COST-EFFECTIVENESS OF SCALING-UP CERVICAL CANCER SCREENING RATES AND HPV VACCINE INITIATION IN TURKEYSozmen, M.K. / K.O.C., E.M. / Kaplan, Y.C. et al. | 2018
-
PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESSNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
-
PCN195 - COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAINGonzález-Domínguez, A. / Moya, C. / Simón, S. / Jiménez-Torres, M. / Bayo-Lozano, E. / Sánchez-Heras, A. / González-Martín, A. et al. | 2018
-
PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGALAlmeida, J. / Tavares, A. / Vandewalle, B. / Félix, J. / Andreozzi, V. / Viana, D.S. et al. | 2018
-
PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANONTfayli, A. / Elias, F. / Farhat, F. / Slim, R. / Hallal, Z. / Maatouk, L. / Ibrahim, A. / Anan, I. et al. | 2018
-
PCN146 - INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOCYTIC LEUKEMIA (ALL): ESTABLISHING A VALUE-BASED COST – PRELIMINARY RESULTSChen, Z. / Xiao, H. / Diaby, V. et al. | 2018
-
PCN123 - EVALUATION OF DRUG THERAPY COSTS FOR PATIENTS WITH BREAST CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW IN 2016-2017Krysanova, V. / Poliakova, K. / Ermolaeva, T. / Davydovskaya, M. / Kokushkin, K. et al. | 2018
-
PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGALAndré, S. / Graça, A. / Soares, V. et al. | 2018
-
PCN98 - PALLIATIVE TREATMENT AND ITS COST IN THE LAST SIX MONTHS OF LIFE FOR METASTATIC COLORECTAL CANCER PATIENTSMerth, G. / Á, Rumszauer / Mokrai, D. / Ruzsa, V. / Füleki, G. / Halmai, L. / Rózsa, P. et al. | 2018
-
PCN95 - A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT'S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)Blein, C. / bernard Marty, C. / Priou, V. / Borg, M.C. / mouret-Reynier, m / Lebozec, G. / Tournamille, J. / Jaffre, A. / PEREZ staub, N. / Alfonsi, R. et al. | 2018
-
PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVEBylicki, O. / Blein, C. / Tournier, C. / Canoui-Poitrine, F. / Chouaid, C. et al. | 2018
-
PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UKSkentzou, E. / Meng, J. / Lister, J. / Gray, L. et al. | 2018
-
PCN52 - PREVALENCE AND INCIDENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: AN EPIDEMIOLOGICAL ANALYSIS BASED ON CLAIMS DATA OF MORE THAN 2.9 MILLION INSURED PERSONSLee, S. / Heidler, T. / Mueller, S. / Wilke, T. / Maywald, U. et al. | 2018
-
PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCERMirza, M.R. / Walder, L. / Monk, B.J. / Tinker, A.V. / Mahner, S. / Gil-Martin, M. / Kalbacher, E. / Waters, J. / Wenham, R.M. / Malander, S. et al. | 2018
-
MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE: AN EVOLVING PROCESSUnsworth, H. / Stevenson, A. et al. | 2018
-
PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLANDTsoumani, E. / Dillon, R.J. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
-
PCV58 - HEALTH INSURANCE TREATMENT COST OF SECONDARY HYPERTENSION IN HUNGARY: A NATIONWIDE COST OF ILLNESS STUDYGazsó, T. / Boncz, I. / Sebestyén, A. / Zemplényi, A. / Gratz, B. / Endrei, D. et al. | 2018
-
PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICESolé, A. / Male, N. / Manganelli, A. / Serra-Burriel, M. et al. | 2018
-
PCV9 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR PEOPLE UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONLewis, S. / Glen, J. / Dawoud, D. / Dias, S. / Cobb, J. / Griffin, X. / Rossiter, N. / Reed, M. / Sharpin, C. / Stansby, G. et al. | 2018
-
PCP50 - PERFORMANCE INDICATORS IN THE MONITORING OF OUTSOURCED PUBLIC HEALTH SERVICESSánchez-Soliño, A. / Sanchez-Solino, O. et al. | 2018
-
PCV39 - ASSESSMENT OF THE BUDGET IMPACT OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM) FOR TREATING IRON DEFICIENCY ANEMIA IN CONGESTIVE HEART FAILURE PATIENTS IN GREECEGkikas, D. / Patos, P. / Parissis, J. / Souliotis, K. et al. | 2018
-
PCV22 - LIPID-LOWERING DRUG PRESCRIPTIONS IN A GROUP OF COLOMBIAN PATIENTS.Machado-Duque, M. / Machado-Alba, J. / Gaviria-Mendoza, A. et al. | 2018
-
PCP30 - COMPARISON REGARDING THE TRANSPARENCY OF REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS USED TO TREAT DEPRESSION IN HUNGARY, ROMANIA, TURKEY AND CISDaneasa, D. / Csanadi, M. / Baran, A. / Subtirelu, M. / Preda, A.L. / Petrescu, M. / Pinyazhko, O. / Holownia-Voloskova, M. / Atikeler, K. et al. | 2018
-
PCP36 - IMPROVING THE QUALITY OF MEDICAL CARE IN HYPERTENSIVE DISORDERS DURING PREGNANCYRubtsova, I. / Lishchyshyna, O. et al. | 2018
-
PCP20 - A MODERN MEDICAL KNOWLEDGE IN MANAGEMENT OF PATIENTS WITH TUBERCULOSIS IN UKRAINELishchyshyna, O. / Migel, O. et al. | 2018
-
PCN351 - HEALTH-STATE UTILITY VALUES IN DIFFUSE LARGE B-CELL LYMPHOMAWang, H. / Manca, A. / Crouch, S. / Bagguley, T. / Yu, G. / Aas, E. / Howell, D. / Burton, C. / Patmore, R. / Roman, E. et al. | 2018
-
PCN370 - COMPARISONS ON THE CHANGE OF PSYCHOSOCIAL ILLNESS IMPACT ACROSS FOUR CANCER SURVIVORSYao, G. / Lai, J. / Garcia, S. / Yount, S. / Cella, D. et al. | 2018
-
PCN355 - UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS: KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGSGalasso, A. / Kandel, M. / Borget, I. et al. | 2018
-
PCN313 - HOSPITAL BASED HEALTH TECHNOLOGY ASSESSMENT PROGRAM AT KING HUSSEIN CANCER CENTER: ASSESSMENT OF FIVE YEARS EXPERIENCERabayah AA, Al / Jaddoua, S. et al. | 2018
-
PCN309 - DIVERSITY IN SAFETY DATA ANALYSES IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMAClaes, A. / Kossow, S. / Italia, N. / Stückemann, V. / Kulp, W. et al. | 2018
-
PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY: A LANDSCAPE ANALYSISCarlson, J.J. / Chen, S. / Dhanda, D.S. / Ramsey, S.D. et al. | 2018
-
PCN312 - HOW HAS THE RELAUNCHED CANCER DRUGS FUND AFFECTED NICE'S APPROVAL OF NOVEL ONCOLOGY TECHNOLOGIES?Illingworth, N. / Shaw, C. / Crutwell, J.R. / Miller, R. / Fountain, D. et al. | 2018
-
PCN294 - THE PATIENT JOURNEY OF MEN WITH LOCALISED PROSTATE CANCER: RESULTS FROM A QUALITATIVE STUDY IN GREECETsiantou, V. / Karampli, E. / Magoulas, C. / Maina, A. / Naoum, V. / Delakas, D.S. / Ntoumas, K. / Athanasakis, K. / Theodorou, C. / Kyriopoulos, J. et al. | 2018
-
PCN297 - IMPACT OF ECONOMIC SANCTIONS ON ACCESS TO NONCOMMUNICABLE DISEASES MEDICINES IN THE ISLAMIC REPUBLIC OF IRANKheirandish, M. / Varmaghani, M. / Kebriaeezadeh, A. / Cheraghali, A.M. et al. | 2018
-
PCN284 - PRICING AND TIME-TO-MARKET FOR TYROSIN-KINASI INHIBITORS (TKIS) IN ITALYVittoria, G. / Berto, P. et al. | 2018
-
PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES : VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONSBerthelot, A. / Verdoni, L. / Paubel, P. / Boyaval, G. et al. | 2018